Radioimmunotherapy is limited by a variety of factors, including poor tumor penetration of monoclonal antibodies and low levels of intratumoral antigen expression. To address these limitations, a gene therapy strategy was devised to genetically induce tumor cells to express enhanced levels of membrane receptors with high affinity for a radiolabeled peptide. We designated this approach as genetic radioisotope targeting strategy. To this end, an adenoviral vector (AdCMVGRPr) encoding the murine gastrin-releasing peptide receptor (GRPr) was used to achieve a high level of binding of radiolabeled bombesin (BBN). To achieve genetic induction of membrane GRPr specifically to tumor cells, we constructed two adenoviral vectors encoding the GRPr gene under the control of the tumor-specific regulatory elements, DF3 (AdDF3GRPr) or erbB-2 (AderbGRPr). We investigated the binding of [
M onoclonal antibodies (Abs) have been used as tumor-targeting molecules to deliver radiation for cancer therapy and diagnosis. [1] [2] [3] [4] [5] However, there are several limitations to standard radioimmunotherapy and several approaches have been developed to address these limitations. A recent approach has been described in which gene transfer methods were used to express an antigen (Ag) on target cells. 6, 7 In one study, an adenoviral vector was employed to deliver the carcinoembryonic Ag gene to human glioma cells that were targeted in vitro and in vivo with a radiolabeled COL-1 anti-carcinoembryonic Ag monoclonal Ab. Other studies have used adenoviral vectors to induce membrane receptors in vitro that have a high affinity for radiolabeled peptides. 8 -11 The radiolabeled peptides can then be targeted to the expressed membrane receptors. We have termed this approach genetic radioisotope targeting strategy (GRITS). Recently, an adenoviral vector (AdCMVGRPr) encoding the murine gastrin-releasing peptide receptor (GRPr) was used to induce GRPr expression in vitro and in vivo. 12, 13 Bombesin (BBN) analogs have been described that have a higher affinity for the receptor, improved radiolabeling with a variety of radionuclides, and greater in vivo stability. 14 -16 Therefore, gene transfer can be used to induce novel membrane receptors that can be targeted with radionuclides with therapeutic potential.
One limitation of GRITS is the inability to specifically deliver the receptor genes to the tumor cells. Recombinant adenoviruses are efficient gene delivery vectors to a wide range of cell types in vitro and in vivo and have been used in a variety of gene therapy strategies. [17] [18] [19] One limitation of adenoviral vectors is their inability to specifically target tumor cells. One strategy that has been used successfully for tumor-specific expression is the use of tissue-or tumor-specific regulatory sequences to control gene expression following viral infection. 20 In this regard, the oncogene erbB-2 is overexpressed in number of different tumor types, particularly carcinomas of the breast, pancreas, ovary, and gastrointestinal tract. 21, 22 The erbB-2 promoter region contains a binding site for the OB2-1 transcription factor that is responsible for up-regulating transcription in human breast cancer. 23 Recently, the erbB-2 promoter was used to demonstrate specific killing of pancreatic and breast cancer cells with the cytosine deaminase gene with a retroviral vector. 24 The human DF3 (MUC1) gene encodes a high molecular weight glycoprotein that is aberrantly overexpressed by breast cholangiocarcinoma and pancreatic cancer cells. [25] [26] [27] The MUC1 Ag is expressed on the apical surface of the epithelial cells that line the glands or ducts of many tissues. 28 Two GC boxes (Sp1 sites) and a novel trans-acting factor have been identified that are important in regulating the expression of human DF3 breast carcinoma Ag gene. 29 -31 A retroviral vector encoding the thymidine kinase (TK) gene under the control of the DF3 promoter demonstrated specific cell killing in breast carcinoma cell lines following treatment with ganciclovir. 32 Recently, an adenoviral vector encoding the TK gene under the control of the MUC1 promoter has been used in a strategy to eliminate carcinoma cells from hematopoietic stem cells. 33 These promoter elements have potential for specific gene expression using adenoviral vectors. We propose that the ability to restrict receptor gene expression only to tumor cells would allow the specific targeting of the radiolabeled peptides to tumors.
In this study, the production of two adenoviral vectors that encode the GRPr under the control of an erbB-2 or DF3 tumor/tissue-specific promoter element is described. In addition, it is shown that one can specifically induce GRPr expression in human breast and cholangiocarcinoma cell lines using a radiolabeled peptidebinding assay. Thus, we show that one can achieve specific induction of a membrane receptor in a specific manner that can be targeted with a radiolabeled peptide.
MATERIALS AND METHODS

Cell culture
The breast carcinoma cell lines ZR-75-1, SK-BR-3, and MDA-MB-231 as well as the pancreatic cancer cell lines BXPC-3 and ASPC-1 were used in this study (American Type Culture Collection, Manassas, Va). The two cholangiocarcinoma cell lines used in this study, SK-ChA-1 and Oz, were a gift from Dr. S. Vickers (University of Alabama, Birmingham, Ala). The ZR-75-1, BXPC-3, and cholangiocarcinoma cell lines were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), whereas ASPC-1 was maintained in 20% FBS and 2 mM glutamine. MDA-MB-231 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, nonessential amino acids, minimal essential medium vitamins, sodium pyruvate, and glutamine. SK-BR-3 cells were maintained in McCoy's 5A medium supplemented with 10% FBS and glutamine. The murine fibroblast cell line BNR-11, which is stably transfected to express the GRPr gene, was obtained from J. Battey (National Cancer Institute, Bethesda, Md) and was maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 2 mM glutamine and 300 g/mL Geneticin (Life Technologies, Gaithersburg, Md). Cells were grown in a humidified atmosphere (95%) with 5% CO 2 . The cells were passaged using 0.05% trypsin and 5 mM ethylenediaminetetraacetic acid (EDTA).
Recombinant adenoviral vector construction
A 768-base pair (bp) MUC1 promoter sequence described by Abe and Kufe 31 was amplified from purified 293 cell line DNA by polymerase chain reaction (PCR) (sequence of upper primer: 5Ј-GGC GGC CGC TCC TGG CCA GTG GTG GAG, with a 5Ј NotI linker; sequence of lower primer: 5Ј-AGA ATT CAG GCA GGC GCT GGC TGC TTG AGA G, with a 5Ј EcoRI linker). PCR was carried out for 35 cycles at 94°C for 1 minute, 70°C for 1 minute, and 72°C for 1.5 minutes using Taq DNA polymerase (Stratagene, La Jolla, Calif). The amplified product was subcloned into the pT7 Blue vector (Novagene, Madison, Wis). The MUC1 promoter sequence was excised using EcoRI and NotI restriction enzymes (Promega, Madison, Wis) and cloned into an adenoviral shuttle vector, pACMVpLpARS(ϩ) (kindly provided by R. Gerard, University of Texas, Southwestern Medical Center, Dallas, Tex), replacing the cytomegalovirus (CMV) early promoter. The MUC1 promoter was analyzed by digestion with various restriction enzymes (data not shown). The resulting plasmid, pADF3pLpA, was used to construct a GRPr-expressing plasmid. The GRPr gene sequence was obtained by restriction digestion of pACMVGRPrpLpA using XbaI and was cloned into pADF3pLpA at the XbaI site under the MUC1 promoter. The resultant plasmid, pADF3GRPrpLpA, was used to construct AdDF3GRPr recombinant adenoviral vector.
A 288-bp erbB-2 promoter sequence contained in pTHCD500 (kindly provided by J. Harris, Imperial Cancer Research Fund, London, UK) 24 was amplified by PCR (sequence of upper primer: 5Ј-GCG GCC GCT CCG AGG AAA AGT GTG AGA ACG, with a 5Ј NotI linker; sequence of lower primer: 5Ј-GAA TTC CCC TGG TTT CTC CGG TCC CAA TG, with a 5Ј EcoRI linker). PCR was performed for 20 cycles at 95°C for 45 seconds, 45°C for 45 seconds, and 72°C for 1 minute using plaque-forming units (PFU) of DNA polymerase (Stratagene). The amplified product was cloned into pBluescript II KS(ϩ) (Stratagene), excised using EcoRI and NotI restriction enzymes, and cloned into pACMVpLpARS ϩ replacing the CMV promoter. The sequence of the erbB-2 promoter was confirmed by sequencing. The resulting plasmid, pMGV1, was used to clone the GRPr gene at the XbaI site to construct the GRPr-expressing plasmid, pAerbB2GRPrpLpA.
The adenoviral vector (AdCMVGRPr)-encoding murine GRPr gene under the control of the CMV early enhancer/ promoter element has been described previously. 12, 13 pADF3GRPrpLpA and pAerbB2GRPrpLpA shuttle plasmids were used to construct respective recombinant adenoviral vectors using standard homologous recombinant techniques. 34 Briefly, the shuttle plasmid and adenoviral packing vector pJM17 (provided by F. Graham, McMaster University, Hamilton, Ontario, Canada) were cotransfected into low-passage 293 cells using cationic liposome-mediated transfection with N- (1-[2,3-dioleoyloxyl] propyl)-N,N,N-trimethylammonium methylsulfate (Boehringer Mannheim, Indianapolis, Ind). The individual plaques produced from recombination events were isolated and validated for the presence of respective promoters (DF3 and erbB-2), for GRPr, and for the absence of adenoviral E1 gene (wild type (wt)) by PCR. Appropriately validated plaques were purified by three subsequent passages through 293 cells. The final viral isolate was verified by PCR again and by restriction enzyme analysis.
Quantities of the AdDF3GRPr and AderbGRPr suitable for in vitro studies were produced by infecting 293 cells with validated viral stock as described above and were purified by CsCl gradient ultra-centrifugation and dialysis. The purified adenoviral vectors AdDF3GRPr and AderbGRPr were analyzed by PCR for the presence of respective promoter sequences and GRPr gene sequences and were analyzed with HindIII restriction enzyme for the absence of E1A wt viral sequence.
Viral infection
A total of 4 ϫ 10 6 cells were plated into T-75 flasks (Costar) 1 day prior to infection. On the following day, one flask was trypsinized and counted to determine cell number for calculation of the appropriate PFU of adenovirus to achieve the desired multiplicity of infection (MOI). The medium was then removed and replaced with 5 mL of Opti-Mem (Life Technologies), and the indicated MOI of adenovirus was added for 1.5 hours. Next, 10 mL of complete growth medium was added, and the cells were returned to the incubator for 48 hours.
Binding assay
Transduced cells and BNR-11 GRPr ϩ control cells were harvested at 48 hours postinfection or were plated by rinsing twice with phosphate-buffered saline (PBS) and were detached with 4 mM EDTA and 0.05% KCl at 37°C. The cells were then resuspended in 0.1% bovine serum albumin (BSA)/PBS (pH 7.2), counted, centrifuged, and resuspended at 1 ϫ 10 7 cells/ mL. Each set of cells was aliquoted (100 L) into polystyrene test tubes in duplicate followed by addition of 100,000 -150,000 counts per minute (cpm) (50 L) of [ 125 I-Tyr 4 ]BBN (DuPont New England Nuclear Research Products, Boston, Mass). Nonspecific binding was determined by the addition of a 1000-fold molar excess of unlabeled BBN. The solutions were shaken at room temperature for 1 hour, rinsed with 0.1% BSA/PBS (pH 7.2), and centrifuged at 1500 revolutions per minute for 10 minutes. The supernatant was removed, and cells were counted in a gamma counter to determine the amount of bound radioactivity. The results were plotted as the percentage of the cpm specifically bound to the cells versus the total cpm added.
Immunochemistry
Our methods of performing and of evaluating immunohistochemistry have been described in the literature 35, 36 as has the immunohistochemical evaluation of cells grown on coverslips. 37 In brief, the formalin-fixed coverslips were permeabilized with acetone and soaked in tris(hydroxymethyl)aminomethanebuffered saline (TBS) (0.5 M tris(hydroxymethyl)aminomethane base, 0.15 M NaCl, Triton X-100 (4 drops/L), pH 7.6) for 5 minutes. The endogenous peroxidase activity of the cells was quenched with an aqueous solution of 3% hydrogen peroxide for 3 minutes, followed by three rinses with TBS. All subsequent washes were performed with TBS. The coverslips were incubated with 1% goat sera to reduce nonspecific background staining followed by incubation with the appropriate primary Ab. Abs were diluted with PBS containing 1% BSA, 1 mM EDTA, and 15 mM NaN 3 (pH 7.6).
The two monoclonal Abs used were the 20 to 1 mixture of the cytokeratins AE1/AE3 (1/200 dilution, 5 g/mL, Boehringer Mannheim) and MUC1 (1/200 dilution, Novacastra, Newcastle on Tyne, UK). Each was incubated for 1 hour at room temperature. A Super Sensitive biotin-streptavidin horseradish peroxidase detection kit (BioGenex, San Ramon, Calif) was used as the secondary detection system. Sections were incubated with biotinylated goat anti-mouse and streptavidin peroxidase (1/40 dilution) for 20 minutes each with TBS washes between steps. For visualization of the Ab-Ag complex, sections were incubated with the diaminobenzidine tetrachloride Super Sensitive substrate kit (BioGenex) for 3 minutes. The remainder of the staining procedure was performed as described elsewhere, 37 as was the immunohistochemical evaluation. 35 The immunostaining of the cells on the coverslips was evaluated by estimating the proportion of cells staining at specific intensities of staining from 0 (no staining) to 4 (maximal staining). The immunostaining score is derived by multiplying the decimal equivalent of the percentage of cells staining at each intensity by the intensity of staining and adding the scores over the five intensities to obtain a score that ranges from 0 to 4.
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RESULTS
Construction and confirmation of recombinant adenoviral vectors
Recombinant adenoviral vectors encoding the GRPr gene under the control of the DF3 (AdDF3GRPr or erbB-2 (AderbGRPr) promoters were constructed. The schema used to generate the recombinant adenoviral vectors AdDF3GRPr and AderbGRPr used standard methods and is shown for AdDF3GRPr in Figure 1 . The methodology for recombinant adenovirus construction is based on in vivo homologous recombination between the recombinant adenoviral shuttle vector and the adenoviral packaging plasmid pJM17. The adenoviral shuttle vector containing the GRPr gene with the DF3 promoter element, pACDF3GRPrpLpARS(ϩ), was constructed and used to derive the corresponding adenoviral vector. The resulting adenoviral vector, AdDF3GRPr, would be predicted to contain the GRPr expression cassette inserted in place of deleted adenoviral E1 sequences (Fig  2A) . A similar result would be expected for AderbGRPr generated from pACerbGRPrpLpARS(ϩ) (map not shown).
Cotransfection of the adenoviral shuttle vector pACDF3GRPrpLpARS(ϩ) or pACerbGRPrpLpARS(ϩ) and the packaging plasmid pJM17 in the E1A transcomplementing cell line 293 resulted in multiple areas of cytopathic effect consistent with adenoviral replication. Analysis of the viral DNA by PCR demonstrated the presence of recombinant adenoviruses possessing characteristics consistent with the GRPr-expressing vectors predicted in Figure 1 . Amplification of AdDF3GRPr or AderbGRPr genomic DNA containing the GRPr gene with GRPr-specific primers yielded the expected PCR fragment of 974 bp in both vectors (Fig 2B) . In Figure  2B (lanes 2 and 6) , an analysis of AdDF3GRPr and AderbGRPr genomic DNA yielded the predicted bands for the DF3-and erbB-2-specific primers, respectively. An analysis of E1A sequences using adenovirus E1A-specific primers indicated the predicted PCR product of 1070 bp from genomic DNA of the Ad2 adenovirus. In contrast, this fragment was absent in the amplification of AdDF3GRPr and AderbGRPr DNA, confirming the absence of E1A sequences in these recombinant adenoviruses. PCR analysis is consistent with the derivation of E1A Ϫ , GRPr-encoding recombinant adenoviruses under the control of either the DF3 or erbB-2 promoter elements and also indicated that no wt virus had been rescued by propagation.
To verify the overall integrity of the adenoviral vectors, restriction analysis of genomic DNA of AdDF3GRPr and AderbGRPr was performed (Fig 2C) . Analysis with a series of restriction endonucleases confirmed that the overall configuration of the recombinant genomes corresponded to the predicted structure. These results demonstrate the production of replication-defective adenoviral vectors that encode the GRPr gene under the control of the DF3 and erbB-2 promoter elements.
Tumor cell-specific expression using the erbB-2 promoter element We tested the ability of the AderbGRPr vector to direct specific gene expression in three human breast cancer cell lines: SK-BR-3, ZR-75-1 erbB-2 ϩ , and MDA-MB-231 erbB-2 Ϫ . 38, 39 The specific binding of [ 125 I]BBN to the induced GRPr receptor served as the assay to assess gene expression. The amount of binding was quantified as the percentage of bound radioactivity compared with the total radioactivity added. The AdCMVGRPr virus showed high levels of GRPr gene expression that increased with increasing MOIs of 50, 200, and 500 (Fig 3) in the three breast cancer cell lines tested. The percentages of [ 125 I]BBN binding for AdCMVGRPr at MOIs of 50, 200, and 500 were 46%, 54%, and 66% for MDA- Figure 1 . Schema for the generation of recombinant GRPr-encoding adenovirus under the control of the DF3 promoter element. The GRPr gene was subcloned into the sites of pACDF3pLpARS(ϩ) to form the plasmid pACDF3GRPrpLpARS(ϩ). The GRPr expression shuttle vector and the adenoviral packaging plasmid pJM17 were cotransfected into 293 cells to generate the recombinant GRPr-encoding adenovirus under the control of the DF3 promoter element.
MB-231; 54%, 73%, and 77% for ZR-75-1; and 68%, 72%, and 74% for SK-BR-3, respectively. The BNR-11 cells served as a positive control and demonstrated 58% [ 125 I]BBN binding. However, only the two erbB-2 ϩ cell lines showed a high level of BBN binding following infection with AderbGRPr (Fig 3) that also increased as the MOI was increased. The percentages of [ 125 I]BBN binding for AderbGRPr at MOIs of 50, 200, and 500 were 8%, 7%, and 12% for MDA-MD-231; 29%, 38%, and 56% for ZR-75-1; and 15%, 28%, and 50% for SK-BR-3, respectively. The level of GRPr gene expression was not as great for the erbB-2 promoter as it was for the CMV promoter. At an MOI of 500, the percentage of binding of AderbGRPr versus AdCMVGRPr was 18%, 73%, and 68% for MDA-MB-231, ZR-75-1, and SK-BR-3, respectively. Therefore, we were able to achieve specific gene expression using the erbB-2 promoter in an adenoviral vector at moderate levels relative to the CMV promoter.
Tumor cell-specific expression using the DF3 promoter element The same breast cancer cell lines were tested with the AdDF3GRPr vector using the same binding assay. We observed specific GRPr gene expression using the AdDF3GRPr vector (Fig 4) . for AdDF3GRPr at MOIs of 50, 200, and 500 were 10%, 11%, and 10% for MDA-MB-231; 25%, 51%, and 62% for ZR-75-1; and 18%, 41%, and 65% for SK-BR-3 cells, respectively. At an MOI of 500, the percentage of binding of AdDF3GRPr versus AdCMVGRPr was 16%, 102%, and 88% for MDA-MB-231, ZR-75-1, and SK-BR-3 cells, respectively. Therefore, we were able to demonstrate a specific and high level of gene expression using the DF3 promoter element in breast cancer cell lines.
We are also interested in using GRITS in pancreatic and cholangiocarcinoma tumor models. To this end, we tested the DF3 promoter in two human pancreatic cell lines, BXPC-3 and ASPC-1, and in two human cholangiocarcinoma cell lines, SK-ChA-1 and Oz. Figure 5 shows specific GRPr gene expression in one pancreatic cell line, ASPC-1, and in one cholangiocarcinoma cell line, SK-ChA-1. The percentages of [ 125 I]BBN binding for AdCMVGRPr at MOIs of 50, 200, and 500 were 21%, 31%, and 48% for BXPC-3; 36%, 63%, and 64% for ASPC-1; 21%, 39%, and 70% for SK-ChA-1; and 45%, 58%, and 70% for Oz cells, respectively. The percentages of [ 125 I]BBN binding for AdDF3GRPr at MOIs of 50, 200, and 500 were 2%, 4%, and 3% for BXPC-3 and 14%, 20%, and 18% for ASPC-1 cells, respectively. However, the DF3-mediated GRPr expression in ASPC-1 was not as great as the other DF3 ϩ cell lines and did not increase with increasing MOIs. The SK-ChA-1 cell line gave results that were similar to the breast cancer cell lines (17%, 33%, and 51% compared with 5%, 5%, and 10% for Oz cells at MOIs of 50, 200, and 500, respectively, with AdDF3GRPr). Therefore, the DF3 promoter can be used to achieve tumor-specific gene expression in breast, pancreatic, and cholangiocarcinoma cells expressing DF3. Weak tumor-specific gene expression was observed in one pancreatic cell line.
Immunohistochemical analysis of MUC1 expression and correlation with [ Fig 6) . A similar result was observed for the cholangiocarcinoma cell lines. SK-ChA-1 cells had a higher level of MUC1 expression compared with Oz cells, which corresponded to a higher level of [
125 I]BBN binding to AdDF3GRPr-infected cells (Table 1 and Fig 6) . The pancreatic cell lines showed a different relationship. Whereas BXPC-3 cells had an intermediate level of MUC1 expression, GRPr expression after infection with AdDF3GRPr was very low (Table 1 and Fig 7) . However, GRPr expression after infection with AdCMVGRPr was lower in BXPC-3 cells than in the other cell lines. ASPC-1 cells had a low of level MUC1 expression but a higher level of GRPr expression following AdDF3GRPr infection compared with BXPC-3 cells. GRPr expression was higher in AdCMVGRPrinfected ASPC-1 cells than in BXPC-3 cells. All cell lines were positive for control cytokeratin staining. Therefore, the expression of MUC1 correlated well with GRPr expression using AdDF3GRPr in breast and cholangiocarcinoma cell lines; however, this finding was not seen in the pancreatic cell lines.
DISCUSSION
We have constructed two adenoviral vectors using the erbB-2 and DF3 promoter elements encoding the membrane receptor GRPr. The AderbGRPr vector was used to obtain specific gene expression in breast cancer cells. GRPr-specific expression was obtained in breast and cholangiocarcinoma cells using the DF3 promoter element and was observed to a lesser degree in pancreatic cell lines. The DF3 promoter element has been used previously with the ZR-75-1 human breast cancer cell line that overexpresses MUC1 to show specific gene expression. 29, 30, 33 The DF3 promoter element was used successfully in our study to achieve a high level of gene expression that increased with increasing viral MOIs in a specific manner in ZR-75-1 and SK-BR-3 breast cancer cell lines. The DF3 promoter was also used to induce specific gene expression in a human cholangiocarcinoma cell line, SK-ChA-1, in a viral dose-dependent manner; SK-ChA-1 has not been reported previously to overexpress MUC1. A high level of MUC1 expression was demonstrated in the SK-ChA-1 cell line by immunohistochemistry. BXPC-3 cells with intermediate MUC1 expression showed no GRPr expression following AdDF3GRPr infection. In contrast, ASPC-1 cells with low MUC1 expression had low GRPr expression that did not increase with increasing MOIs of AdDF3GRPr. AdCMVGRPr-infected BXPC-3 cells had lower GRPr expression than other AdCMVGRPr-infected cell lines at all MOIs tested. There was a lack of GRPr expression in AdDF3GRPr-infected BXPC-3 cells despite an intermediate MUC1 expression level. Higher GRPr expression in AdDF3GRPr-infected ASPC-1 cells compared with BXPC-3 cells was observed despite lower MUC1 expression in ASPC-1 cells. Thus, in the pancreatic cell lines tested, the level of AdDF3GRPr-induced gene expression did not correlate with MUC1 expression for unknown reasons.
One goal of this study was to apply the use of transcriptional targeting with the GRITS approach. 10 It was shown that one can induce a novel membrane receptor in a specific manner and then target that receptor with a radiolabeled peptide. The ability to specifically express membrane receptors on cancer cells should allow delivery of a genotoxic agent only to the target cells. The use of the GRITS approach may overcome some of the limitations of conventional radioimmunotherapy; in addition, when combined with transcriptional targeting as described here, GRITS may lead to greater selective delivery of the radiolabeled peptide. Several reports have demonstrated the usefulness of transcriptional targeting using adenoviral vectors, including the DF3 promoter. 33,40 -47 However, other investigators have had difficulty achieving conditional gene expression in adenoviral vectors. 48, 49 One of the promoters in this study, erbB-2, was used previously in an adenoviral vector by Ring et al. 39 These researchers showed that the TK gene lost its specificity in the adenoviral background, whereas a retrovirus and the plasmid demonstrated specific gene expression. They used these data to hypothesize that it was not a gene effect that led to the loss of specific gene expression in the adenoviral vector. We obtained a similar result using the erbB-2 promoter with the luciferase gene (data not shown). However, using the GRPr gene, we observed very specific gene expression in the same cell lines and with the same promoter as Ring et al. 39 From our experience and what others have achieved using adenoviral vectors with specific transcriptional control elements, we believe that each gene of interest and the particular control element will have to be tested empirically for efficacy.
The success we have observed with these particular promoter elements and the GRPr gene will allow us to test the ability to specifically deliver the receptor gene in vivo using an appropriate model. The ability to achieve specific gene expression should increase the therapeutic ratio by delivering a greater dose to the tumor while limiting the radiation dose to surrounding normal tissue. One limitation of the GRITS approach is the loss of targeting to systemic disease following the systemic administration of adenovirus. The ability to deliver vectors systemically and obtain gene expression only in tumor cells could extend the GRITS approach to systemic disease. The use of transcriptional targeting using tumor-specific promoter elements is one potential method to deliver genes coding for receptors specifically to tumor cells in an appropriate animal model. Thus, adenoviral vectors with tissue-specific promoter elements can be used to achieve a selective expression of membrane receptors that can be targeted with a radiolabeled peptide. The use of such a transcriptional targeting approach may restrict gene expression to tumors and limit the radiation dose deposited in normal tissues in vivo. 
